Circulating Tumor DNA After Neoadjuvant Chemotherapy
ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut Bergonié
About this trial
Trial assessing the prognostic value of ctDNA mutations from samples taken sequentially in patients with invasive breast cancer initially treated with neoadjuvant chemotherapy and whose tumor is not in complete histological response.
Eligibility criteria
Qualifiers
Age ≥ 18 years (no age limit).
Women or men.
cT4a, b, c, d whatever the cN
or cN2 or cN3 whatever the cT.
Disqualifiers
cT2cN0 tumor without cytological or histological lymph node involvement.
Progression during neoadjuvant chemotherapy.
Exclusive neoadjuvant hormone therapy.
Complete blood transfusion within 120 days prior to 1st sampling.
Trial design
Treatments tested in this trial
- Follow-up after neoadjuvant chemotherapy
Treatment groups
180 Participants
are divided into 1 treatment groupSponsors and collaborators
Institut Bergonié
Lead sponsor
Fondation Bergonié
Collaborator
Source ClinicalTrials.gov